vs
Side-by-side financial comparison of Esperion Therapeutics, Inc. (ESPR) and EverQuote, Inc. (EVER). Click either name above to swap in a different company.
EverQuote, Inc. is the larger business by last-quarter revenue ($195.3M vs $168.4M, roughly 1.2× Esperion Therapeutics, Inc.). On growth, Esperion Therapeutics, Inc. posted the faster year-over-year revenue change (143.7% vs 32.5%). Over the past eight quarters, EverQuote, Inc.'s revenue compounded faster (46.5% CAGR vs 10.6%).
Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.
EverQuote, Inc. is an online insurance marketplace founded in 2011 and based in Cambridge, Massachusetts.
ESPR vs EVER — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $168.4M | $195.3M |
| Net Profit | — | $57.8M |
| Gross Margin | — | 97.7% |
| Operating Margin | 50.6% | 9.5% |
| Net Margin | — | 29.6% |
| Revenue YoY | 143.7% | 32.5% |
| Net Profit YoY | — | 369.3% |
| EPS (diluted) | $0.32 | $1.53 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $168.4M | $195.3M | ||
| Q3 25 | $87.3M | $173.9M | ||
| Q2 25 | $82.4M | $156.6M | ||
| Q1 25 | $65.0M | $166.6M | ||
| Q4 24 | $69.1M | $147.5M | ||
| Q3 24 | $51.6M | $144.5M | ||
| Q2 24 | $73.8M | $117.1M | ||
| Q1 24 | $137.7M | $91.1M |
| Q4 25 | — | $57.8M | ||
| Q3 25 | $-31.3M | $18.9M | ||
| Q2 25 | $-12.7M | $14.7M | ||
| Q1 25 | $-40.5M | $8.0M | ||
| Q4 24 | — | $12.3M | ||
| Q3 24 | $-29.5M | $11.6M | ||
| Q2 24 | $-61.9M | $6.4M | ||
| Q1 24 | $61.0M | $1.9M |
| Q4 25 | — | 97.7% | ||
| Q3 25 | — | 97.3% | ||
| Q2 25 | — | 96.9% | ||
| Q1 25 | — | 96.8% | ||
| Q4 24 | — | 96.3% | ||
| Q3 24 | — | 96.2% | ||
| Q2 24 | — | 95.7% | ||
| Q1 24 | — | 94.5% |
| Q4 25 | 50.6% | 9.5% | ||
| Q3 25 | -11.4% | 10.1% | ||
| Q2 25 | 8.6% | 9.0% | ||
| Q1 25 | -34.0% | 4.8% | ||
| Q4 24 | -6.4% | 8.2% | ||
| Q3 24 | -31.0% | 8.1% | ||
| Q2 24 | 3.5% | 5.4% | ||
| Q1 24 | 52.5% | 1.9% |
| Q4 25 | — | 29.6% | ||
| Q3 25 | -35.9% | 10.8% | ||
| Q2 25 | -15.4% | 9.4% | ||
| Q1 25 | -62.2% | 4.8% | ||
| Q4 24 | — | 8.3% | ||
| Q3 24 | -57.2% | 8.0% | ||
| Q2 24 | -83.9% | 5.5% | ||
| Q1 24 | 44.3% | 2.1% |
| Q4 25 | $0.32 | $1.53 | ||
| Q3 25 | $-0.16 | $0.50 | ||
| Q2 25 | $-0.06 | $0.39 | ||
| Q1 25 | $-0.21 | $0.21 | ||
| Q4 24 | $-0.14 | $0.35 | ||
| Q3 24 | $-0.15 | $0.31 | ||
| Q2 24 | $-0.33 | $0.17 | ||
| Q1 24 | $0.34 | $0.05 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $167.9M | $171.4M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-302.0M | $238.0M |
| Total Assets | $465.9M | $326.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $167.9M | $171.4M | ||
| Q3 25 | $92.4M | $145.8M | ||
| Q2 25 | $86.1M | $148.2M | ||
| Q1 25 | $114.6M | $125.0M | ||
| Q4 24 | $144.8M | $102.1M | ||
| Q3 24 | $144.7M | $82.8M | ||
| Q2 24 | $189.3M | $60.9M | ||
| Q1 24 | $226.6M | $48.6M |
| Q4 25 | $-302.0M | $238.0M | ||
| Q3 25 | $-451.4M | $174.9M | ||
| Q2 25 | $-433.5M | $170.3M | ||
| Q1 25 | $-426.2M | $149.5M | ||
| Q4 24 | $-388.7M | $135.4M | ||
| Q3 24 | $-370.2M | $117.7M | ||
| Q2 24 | $-344.2M | $100.8M | ||
| Q1 24 | $-294.3M | $88.3M |
| Q4 25 | $465.9M | $326.9M | ||
| Q3 25 | $364.0M | $256.1M | ||
| Q2 25 | $347.1M | $241.4M | ||
| Q1 25 | $324.0M | $232.1M | ||
| Q4 24 | $343.8M | $210.5M | ||
| Q3 24 | $314.1M | $180.5M | ||
| Q2 24 | $352.3M | $158.0M | ||
| Q1 24 | $373.1M | $135.4M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $45.2M | $27.0M |
| Free Cash FlowOCF − Capex | — | $25.8M |
| FCF MarginFCF / Revenue | — | 13.2% |
| Capex IntensityCapex / Revenue | 0.0% | 0.6% |
| Cash ConversionOCF / Net Profit | — | 0.47× |
| TTM Free Cash FlowTrailing 4 quarters | — | $90.3M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $45.2M | $27.0M | ||
| Q3 25 | $-4.3M | $19.8M | ||
| Q2 25 | $-31.4M | $25.3M | ||
| Q1 25 | $-22.6M | $23.3M | ||
| Q4 24 | $-35.0M | $20.1M | ||
| Q3 24 | $-35.3M | $23.6M | ||
| Q2 24 | $-7.2M | $12.4M | ||
| Q1 24 | $53.8M | $10.4M |
| Q4 25 | — | $25.8M | ||
| Q3 25 | — | $18.5M | ||
| Q2 25 | — | $23.8M | ||
| Q1 25 | — | $22.2M | ||
| Q4 24 | — | $19.1M | ||
| Q3 24 | $-35.5M | $22.1M | ||
| Q2 24 | $-7.3M | $11.5M | ||
| Q1 24 | $53.8M | $9.7M |
| Q4 25 | — | 13.2% | ||
| Q3 25 | — | 10.6% | ||
| Q2 25 | — | 15.2% | ||
| Q1 25 | — | 13.3% | ||
| Q4 24 | — | 13.0% | ||
| Q3 24 | -68.7% | 15.3% | ||
| Q2 24 | -9.9% | 9.8% | ||
| Q1 24 | 39.0% | 10.6% |
| Q4 25 | 0.0% | 0.6% | ||
| Q3 25 | 0.0% | 0.7% | ||
| Q2 25 | 0.0% | 0.9% | ||
| Q1 25 | 0.0% | 0.7% | ||
| Q4 24 | 0.0% | 0.7% | ||
| Q3 24 | 0.3% | 1.0% | ||
| Q2 24 | 0.1% | 0.7% | ||
| Q1 24 | 0.1% | 0.8% |
| Q4 25 | — | 0.47× | ||
| Q3 25 | — | 1.05× | ||
| Q2 25 | — | 1.72× | ||
| Q1 25 | — | 2.92× | ||
| Q4 24 | — | 1.64× | ||
| Q3 24 | — | 2.04× | ||
| Q2 24 | — | 1.93× | ||
| Q1 24 | 0.88× | 5.47× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
EVER
| Automotive | $179.9M | 92% |
| Home And Renters | $15.4M | 8% |
